X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
1. 2',3',5'-tri-o-acetyluridine
2. Pn 401
3. Pn-401
4. Pn401
5. Rg-2133
6. Rg2133
7. Triacetyluridine
8. Xuriden
1. 4105-38-8
2. 2',3',5'-tri-o-acetyluridine
3. Triacetyluridine
4. Vistonuridine
5. Pn401
6. 2',3',5'-triacetyluridine
7. Xuriden
8. Tri-o-acetyluridine
9. Uridine 2',3',5'-triacetate
10. Vistogard
11. (2r,3r,4r,5r)-2-(acetoxymethyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)tetrahydrofuran-3,4-diyl Diacetate
12. Triacetyl Uridine
13. Uridine, 2',3',5'-triacetate
14. Pn 401
15. Pn-401
16. Rg2133
17. Rg 2133
18. Rg-2133
19. Mfcd00023795
20. 2wp61f175m
21. Unii-2wp61f175m
22. Uridinetriacetate
23. Uridine Triacetate [usan:inn]
24. Uridine-triacetate
25. Vistogard (tn)
26. Einecs 223-881-5
27. Xuriden (tn)
28. Uridine, 2,3,5-triacetate
29. Mls006009982
30. Schembl871011
31. Uridine Triacetate [mi]
32. Chembl2107381
33. Uridine Triacetate (usan/inn)
34. Uridine Triacetate [inn]
35. Chebi:90914
36. Dtxsid40961409
37. Uridine Triacetate [usan]
38. [(2r,3r,4r,5s)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl Acetate
39. Cs-d1799
40. Uridine Triacetate [who-dd]
41. Zinc3843198
42. Nsc788948
43. S6484
44. Akos015964563
45. Db09144
46. Nsc-788948
47. [(2r,3r,4r,5r)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl Acetate
48. Uridine Triacetate [orange Book]
49. Hy-14905
50. Smr004701034
51. Sy004945
52. 2',3',5'-tri-o-acetyluridine, >=98%
53. D09985
54. 105t388
55. A825419
56. J-700012
57. Q22075857
58. Uridine 2',3',5'-triacetate;2',3',5'-triacetyluridine
59. 2 Inverted Exclamation Mark ,3 Inverted Exclamation Mark ,5 Inverted Exclamation Mark -triacetyluridine
| Molecular Weight | 370.31 g/mol |
|---|---|
| Molecular Formula | C15H18N2O9 |
| XLogP3 | -0.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 8 |
| Exact Mass | 370.10123016 g/mol |
| Monoisotopic Mass | 370.10123016 g/mol |
| Topological Polar Surface Area | 138 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 660 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Marketed as the product Xuriden (FDA), uridine triacetate is indicated for the treatment of hereditary orotic aciduria. Marketed as the product Vistogard (FDA), uridine triacetate is indicated for the emergency treatment of adult and pediatric patients in the following situations: following a fluorouracil or capecitabine overdose regardless of the presence of symptoms; or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.
FDA Label
A - Alimentary tract and metabolism
A16 - Other alimentary tract and metabolism products
A16A - Other alimentary tract and metabolism products
A16AX - Various alimentary tract and metabolism products
A16AX13 - Uridine triacetate
Absorption
Maximum concentrations of uridine in plasma following oral administration are generally achieved within 2 to 3 hours.
Route of Elimination
Uridine can be excreted via the kidneys, but is also metabolized by normal pyrimidine catabolic pathways present in most tissues.
Volume of Distribution
Circulating uridine is taken up into mammalian cells via specific nucleoside transporters, and also crosses the blood brain barrier.
Following oral administration, uridine triacetate is deacetylated by nonspecific esterases present throughout the body, yielding uridine in the circulation.
2 to 2.5 hours
Uridine triacetate is a synthetic uridine pro-drug that is converted to uridine in vivo. When used for the treatment or prevention of toxicity associated with fluorouracil and other antimetabolites, uridine triacetate is utilized for its ability to compete with 5-fluorouracil (5-FU) metabolites for incorporation into the genetic material of non-cancerous cells. It reduces toxicity and cell-death associated with two cytotoxic intermediates: 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). By pre-administering with uridine (as the prodrug uridine triacetate), higher doses of 5-FU can be given allowing for improved efficacy and a reduction in toxic side effects such as neutropenia, mucositis, diarrhea, and handfoot syndrome. Uridine triacetate is also used for replacement therapy in the treatment of hereditary orotic aciduria, also known as uridine monophosphate synthase (UMPS) deficiency. As a result of UMPS deficiency, patients experience a systemic deficiency of pyrimidine nucleotides, accounting for most symptoms of the disease. Additionally, orotic acid from the de novo pyrimidine pathway that cannot be converted to UMP is excreted in the urine, accounting for the common name of the disorder, orotic aciduria. Furthermore, orotic acid crystals in the urine can cause episodes of obstructive uropathy. When administered as the prodrug uridine triacetate, uridine can be used by essentially all cells to make uridine nucleotides, which compensates for the genetic deficiency in synthesis in patients with hereditary orotic aciduria.
Market Place
